Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Tempus AI, Inc. Class A ( (TEM) ) has issued an update.
Tempus AI, Inc. announced preliminary, unaudited financial results for the fourth quarter and full year 2024, highlighting a 30% year-over-year revenue growth to approximately $693 million and improved adjusted EBITDA. Despite some challenges in CRO revenues, the company maintained strong momentum in core businesses, with significant growth in genomics and data services expected to meet revenue and adjusted EBITDA guidance for 2024. Tempus is set to present at the J.P. Morgan Healthcare Conference and plans to report final financial results in its first earnings call of 2025.
More about Tempus AI, Inc. Class A
Tempus AI, Inc. is a technology company advancing precision medicine by leveraging artificial intelligence in healthcare. It operates one of the world’s largest libraries of multimodal data, providing AI-enabled solutions for personalized patient care, and facilitating the discovery, development, and delivery of optimal therapeutics.
YTD Price Performance: 9.55%
Average Trading Volume: 2,437,592
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.91B
For an in-depth examination of TEM stock, go to TipRanks’ Stock Analysis page.
